ÂÜÀòÂÒÂ×

Karen Boezi is a seasoned executive with extensive experience in the life sciences and biotechnology sectors. Currently serving as Chief Operating Officer at Thirona Bio since February 2023, Boezi leads efforts in developing novel drugs for fibrotic diseases. As a Board Member at Acrigen Biosciences since April 2019, Boezi contributes to advancements in precision gene editing systems utilizing CRISPR for human therapeutics. Boezi has been a member of Broadway Angels since May 2015, investing in private companies alongside fellow Partner-level investors and executives. Previously, Boezi held the position of CEO at Redwood Bioscience from September 2009 until its acquisition by Catalent, where the firm pioneered precision-protein engineering for antibody-drug conjugates. Additionally, Boezi co-founded Thomas, McNerney & Partners, a venture capital firm focused on life sciences, and has held various roles at Coral Ventures, Warburg Pincus, and Alex. Brown & Sons. Boezi earned a B.S. in Economics with a concentration in Finance from The Wharton School.